Neoral in liver transplantation

Area of Science:

• Pharmacology
• Drug Formulation
• Clinical Pharmacokinetics

Background:

• Sandimmune (cyclosporine) absorption can be variable and bile-dependent.
• Certain medical conditions (cystic fibrosis, pancreatitis, Crohn's disease) and the early postoperative period pose challenges for effective Sandimmune absorption.
• Predictable drug monitoring is crucial for optimizing therapeutic outcomes.

Purpose of the Study:

• To evaluate the pharmacokinetic advantages of Neoral compared to Sandimmune.
• To assess the clinical utility of Neoral in specific patient populations and settings.
• To determine the correlation between Neoral trough blood levels and overall drug exposure (AUC).

Main Methods:

• Pharmacokinetic studies comparing Neoral and Sandimmune formulations.
• Clinical observations in patients with malabsorption syndromes and in the early postoperative period.
• Analysis of bile independence of Neoral absorption.

Main Results:

• Neoral demonstrates more consistent drug absorption and enhanced pharmacokinetic predictability.
• A strong correlation exists between Neoral trough blood levels and drug exposure (AUC), validating trough levels as a monitoring parameter.
• Neoral absorption is bile-independent, improving its use in cholestasis, rejection, and postoperatively.
• Conversion to Neoral corrects cyclosporine (CyA) malabsorption in patients with conditions like cystic fibrosis, pancreatitis, and Crohn's disease.

Conclusions:

• Neoral offers significant pharmacokinetic advantages over Sandimmune, including improved absorption consistency and predictability.
• The bile-independent absorption of Neoral enhances its therapeutic utility in challenging clinical scenarios.
• Neoral effectively addresses malabsorption issues in specific patient groups, improving cyclosporine delivery.
• Future research should investigate long-term toxicity, potential for steroid-sparing, and impact on acute and chronic rejection rates.